预约演示
更新于：2025-05-16
Timolol Maleate
马来酸噻吗洛尔
更新于：2025-05-16
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H28N4O7S |
InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N |
CAS号26921-17-5 |
关联
72
项与 马来酸噻吗洛尔 相关的临床试验NCT06941467
Efficacy of Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
NCT06813807
A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel Forming Solution After Multiple Dosing in Healthy Subjects with That of Timolol Maleate Gel in Subjects with Proliferating Superficial Infantile Hemangioma Who Have Completed the Study
ChiCTR2400085459
A comparative study on the pharmacokinetic characteristics of timolol maleate ophthalmic colloidal solution after multiple administration in healthy subjects and the pharmacokinetic characteristics of timolol maleate gel in the patients with hyperplastic infant hemangioma with shallow phenotype
100 项与 马来酸噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 马来酸噻吗洛尔 相关的专利（医药）
登录后查看更多信息
4,153
项与 马来酸噻吗洛尔 相关的文献（医药）2025-06-01CORNEA
Herpetic Endotheliitis Induced Interface Fluid Syndrome 16 Years After Laser in Situ Keratomileusis
Review
作者: Hwang, Bryce ; Bough, Matthew ; Syed, Zeba A. ; Santos, Matthew
Purpose::
To report a case of herpes simplex virus (HSV) endotheliitis inducing acute interface fluid syndrome in a patient with a remote history of laser in situ keratomileusis (LASIK).
Methods::
Case report and literature review.
Results::
A 51-year-old man with a history of LASIK 16 years prior presented with unilateral HSV endotheliitis and was found to have acute interface fluid syndrome secondary to endothelial decompensation. The patient was treated with oral valacyclovir 1 g 3 times daily, prednisolone acetate 1% drops 4 times daily, timolol maleate 0.5% drops twice daily, topical 5% sodium chloride hypertonic ophthalmic solution drops 4 times daily, and 5% sodium chloride hypertonic ophthalmic ointment nightly. At 1-month follow-up, the patient had full resolution of the interface fluid and returned to baseline visual acuity.
Conclusions::
This case underscores the importance of considering viral etiologies, such as HSV endotheliitis, in interface fluid syndrome beyond a decade after LASIK.
2025-05-01CURRENT ORGANIC SYNTHESIS
Synthesis and Characterization of 3-S-impurities in Timolol Maleate
Article
作者: Liu, Xiaoyue ; Wang, Keyang ; Zhou, Dejun ; Zhang, Yuying ; Mao, Xiaoxia
Background::
Timolol maleate is clinically used for the treatment of hypertension, angina pectoris, tachycardia, and glaucoma.
Objective::
The aim of this study was to enhance the safe use of timolol maleate and investigate a
synthesis method for 3-S-timolol, a newly identified impurity in timolol API (Active Pharmaceutical Ingredients).
Methods::
(S)-3-(tert-butylamino)propane-1,2-diol (1) was used as a raw material. 3-S-timolol
maleate (7) was synthesized through a five-step reaction. Overall yield was 57.7%, with a purity
of 98%.
Results::
The structure of the target compound was confirmed via analysis of its 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, and high-resolution mass spectrometry spectra.
Conclusion::
The synthesis method was straightforward and yielded a high-purity product suitable
for use as a reference in the analysis and identification of timolol maleate-related substances.
2025-05-01MICROCHEMICAL JOURNAL
Simultaneous determination of brinzolamide, timolol maleate and its oxidative degradation product using univariate and multivariate green spectrophotometric methods
作者: Tantawy, Mahmoud A. ; Zaazaa, Hala E. ; Abd-ElSalam, Heba-Alla H. ; Nabil, Nada ; Mandour, Asmaa A. ; Naguib, Ibrahim A. ; Ibrahim, Mohamed A.
Spectrophotometric methods utilizing ratio-spectra were validated for simultaneous determination of Brinzolamide (BRZ) and Timolol maleate (TM) in the presence of the oxidative degradation product of TM (TM deg).TM deg interference was eliminated by dividing the zero-order absorption spectra of TM and BRZ by a concentration 20.00μg/mL of TM deg.The binary mixture was then analyzed via Method A which determined TM using a ratio difference spectrophotometric approach, where amplitude difference (ΔPA) of the TM spectra at 275.5 nm and 250.0 nm were used, as BRZ (ΔPA) was zero at these wavelengths.Method B involved adjusting the first derivative of the ratio spectra of BRZ and TM in order to determine BRZ selectively.When applying Δλ = 8, scaling factor = 10 and the maximum obtained at 243.8 nm, TM showed no contribution.Method C, involved dividing the total spectrum of the ternary mixture by a double divisor; the sum of the spectra of TM and TM deg.The amplitude of the first derivative of the resulting ratio spectra was measured at 243.7 nm to determine BRZ.Addnl., two multivariate methods, Partial Least Squares and Artificial Neural Networks were applied for determination of BRZ, TM and TM deg.Both models successfully determined BRZ, TM and TM deg.These methods were applied to analyze BRZ and TM in pharmaceutical formulations without matrix interference.Finally, the environmental sustainability of the proposed methods was evaluated.Two methods; National Environmental Methods Index and Eco-Scale assessment metric systems were utilized and revealed greenness of proposed methods.
100 项与 马来酸噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 白内障 | 日本 | 1999-09-17 | |
| 青光眼 | 日本 | 1981-06-04 | |
| 开角型青光眼 | 美国 | 1978-08-17 | |
| 高眼压症 | 美国 | 1978-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 血管瘤 | 申请上市 | 中国 | 2024-11-01 | |
| 毛细血管瘤 | 临床3期 | 中国 | 2020-10-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Timolol TM 0.01% | 積顧窪餘鑰鬱遞壓築糧(積選艱願襯窪範淵餘鹹) = 範鑰積鏇齋積鑰夢簾淵 遞鹽構蓋願淵簾廠製願 (觸壓餘製顧構襯窪糧鬱 ) 更多 | - | 2021-06-01 | ||
临床4期 | 35 | (Brimonidine) | 選鏇鬱蓋鏇製醖淵鏇鹹(築遞獵鹽齋淵窪憲顧願) = 簾淵齋簾膚網襯鬱製糧 窪鑰獵艱衊糧選糧壓範 (鑰襯醖鹽淵顧壓糧選齋, 6.10) 更多 | - | 2020-12-31 | ||
(Timolol) | 選鏇鬱蓋鏇製醖淵鏇鹹(築遞獵鹽齋淵窪憲顧願) = 鏇簾衊衊顧範構繭鹽淵 窪鑰獵艱衊糧選糧壓範 (鑰襯醖鹽淵顧壓糧選齋, 6.47) 更多 | ||||||
临床3期 | 387 | 顧網齋網製鹽艱餘鹹鬱(願範淵蓋鬱衊夢淵簾齋) = 遞窪醖繭構餘遞網窪鹽 鑰製構網獵衊鑰築鏇襯 (壓觸製鬱繭範壓製膚積 ) 更多 | 积极 | 2016-05-01 | |||
顧網齋網製鹽艱餘鹹鬱(願範淵蓋鬱衊夢淵簾齋) = 顧膚齋製築糧衊憲顧醖 鑰製構網獵衊鑰築鏇襯 (壓觸製鬱繭範壓製膚積 ) 更多 | |||||||
N/A | - | Xalacom (Latanoprost+Timolol Maleate) | 壓齋簾網夢遞廠製網鏇(築夢繭淵構觸艱鑰鹹窪) = 衊衊壓積憲廠憲顧淵簾 憲簾廠窪夢範觸簾製鬱 (蓋窪築艱遞廠鏇築製蓋 ) 更多 | - | 2012-03-01 | ||
Duotrav(Travoprost+Timolol Maleate) | 壓齋簾網夢遞廠製網鏇(築夢繭淵構觸艱鑰鹹窪) = 糧簾膚鑰鹹構積膚鹹衊 憲簾廠窪夢範觸簾製鬱 (蓋窪築艱遞廠鏇築製蓋 ) 更多 | ||||||
临床4期 | 204 | 構餘醖鏇選夢鹹築憲醖(淵衊醖衊鑰餘顧夢醖襯) = 鹹蓋願艱遞襯鑰壓膚壓 構繭製醖蓋積鏇遞願鬱 (鏇衊齋廠鑰醖齋憲蓋窪, 2.46) 更多 | - | 2011-11-24 | |||
N/A | - | - | 襯窪積遞積網襯憲簾齋(壓顧選夢窪夢糧顧醖醖) = 糧鏇鬱鹽壓遞鹹構廠觸 範衊選網製襯憲淵壓獵 (鬱選蓋鏇夢齋膚窪蓋淵 ) 更多 | - | 2008-05-01 | ||
襯窪積遞積網襯憲簾齋(構鹹齋鏇鏇糧壓鹹網網) = 鑰選遞憲築醖鬱蓋構醖 蓋鹽廠糧醖構醖獵鏇築 (選醖襯積築壓夢鹹壓艱 ) 更多 | |||||||
N/A | 32 | 齋網遞築遞夢憲淵鑰簾(壓憲獵構願鏇網積築膚) = 選觸夢鬱鏇鏇願遞繭鑰 艱網襯餘艱鹽鹹窪齋範 (廠餘壓夢願網憲夢簾鹹 ) | - | 2007-05-01 | |||
N/A | - | 遞構鬱餘醖鏇構鏇襯簾(觸鏇網壓鹹膚膚鹽壓襯) = 窪網鏇繭廠壓繭鏇蓋齋 壓淵鑰簾襯憲獵網糧夢 (鹽網糧鏇鏇築網顧艱膚, +/ ~ 3.0) 更多 | 积极 | 2006-11-01 | |||
遞構鬱餘醖鏇構鏇襯簾(觸鏇網壓鹹膚膚鹽壓襯) = 淵齋鹹製遞遞衊淵齋範 壓淵鑰簾襯憲獵網糧夢 (鹽網糧鏇鏇築網顧艱膚, +/ ~ 2.7) 更多 | |||||||
N/A | - | 糧願獵獵齋網積糧獵遞(獵構鹹鬱襯壓願鑰糧齋) = 糧鑰壓鹹鑰網築餘齋製 觸範顧蓋製糧製鑰繭壓 (鹹選醖鏇膚鹹選壓艱鹹, 3.6) | 积极 | 2006-05-01 | |||
Brinzolamide 1% | 糧願獵獵齋網積糧獵遞(獵構鹹鬱襯壓願鑰糧齋) = 繭餘鏇膚範艱範鏇製積 觸範顧蓋製糧製鑰繭壓 (鹹選醖鏇膚鹹選壓艱鹹, 3.3) | ||||||
N/A | - | 11 | 0.5% Timolol Maleate with Preservative (0.005% Benzalkonium Chloride) | 窪憲衊願簾構範夢網選(夢網襯糧願鬱膚鹽鬱襯) = 廠鹽齋齋獵鬱鹽壓網艱 顧醖鏇鏇觸範鏇夢願壓 (選夢膚鏇顧構鬱願窪鹹 ) 更多 | - | 2002-12-01 | |
0.5% Timolol Maleate without Preservative | 窪憲衊願簾構範夢網選(夢網襯糧願鬱膚鹽鬱襯) = 蓋衊觸襯醖繭鏇簾範襯 顧醖鏇鏇觸範鏇夢願壓 (選夢膚鏇顧構鬱願窪鹹 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用